Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose metronidazole bismuth-based quadruple therapy vs clarithromycin-containing concomitant regimen for H. pylori eradication
IRCT20200915048726N3Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of metronidazole, clarithromycin and bismuth subsalicylate in Helicobacter pylori infection (2 arms), sponsored by Mazandaran University of Medical Sciences. Started Dec 2023; status: completed.
02
Drugs
metronidazoleclarithromycinbismuth subsalicylate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20200915048726N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200915048726N3.